Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. DOI:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–791.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang HL, Fang K, et al. International trends in esophageal cancer incidence rates by histological subtype (1990-2012) and prediction of the rates to 2030. Esophagus. 2022;19(4):560–568.
   PubMed Web of Science ®Google Scholar
• Hu SY, Gao HJ, Jiang ZH, et al. A recurrence predictive model for node-negative esophageal squamous cell carcinoma after upfront esophagectomy. Semin Thorac Cardiovasc Surg. 2022;S1043-0679(22)p. 00217–9. DOI:10.1053/j.semtcvs.2022.08.016
   Google Scholar
• Qiu L, Yue J, Ding L, et al. Cancer-associated fibroblasts: an emerging target against esophageal squamous cell carcinoma. Cancer Lett. 2022;546:215860.
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855–883. DOI:10.6004/jnccn.2019.0033
   PubMed Web of Science ®Google Scholar
• Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):34–43. DOI:10.1093/annonc/mdy498
   PubMed Web of Science ®Google Scholar
• An L, Zheng R, Zeng H, et al. The survival of esophageal cancer by subtype in China with comparison to the United States. Int J Cancer. 2023;152(2):151–161. DOI:10.1002/ijc.34232
   PubMed Web of Science ®Google Scholar
• Wada S, Kobayashi S, Tsunoda T. Future prospects for cancer immunotherapy - Strategies for ineffective cancers. Hum Vaccin Immunother. 2022;18(1):2031699.
   PubMed Web of Science ®Google Scholar
• Yang Y, Tan L, Hu J, et al. Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China. Dis Esophagus. 2022;35(11):doac031. DOI:10.1093/dote/doac031
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. DOI:10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–925. DOI:10.1001/jama.2021.12836
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. DOI:10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40(3):277–288.e3. DOI:10.1016/j.ccell.2022.02.007
   PubMed Web of Science ®Google Scholar
• da Veiga C, da Veiga CP, Drummond-Lage AP. Concern over cost of and access to cancer treatments: a meta-narrative review of nivolumab and pembrolizumab studies. Crit Rev Oncol Hematol. 2018;129:133–145.
   PubMed Web of Science ®Google Scholar
• Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):128. DOI:10.1186/s40425-018-0442-7
   PubMed Web of Science ®Google Scholar
• Rice TW, Apperson-Hansen C, DiPaola LM, et al. Worldwide esophageal cancer collaboration: clinical staging data. Dis Esophagus. 2016;29(7):707–714. DOI:10.1111/dote.12493
   PubMed Web of Science ®Google Scholar
• Yue X, Li Y, Wu J, et al. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues. 2021;24:1–5.
   PubMedGoogle Scholar
• State Administration of Foreign Exchange (2021) Table of conversion rates of various currencies to USD. Available at: https://www.safe.gov.cn/safe/gzhbdmyzslb/index.html.accessed Dec 26, 2022).
   Google Scholar
• National Bureau of statistics of China. Statistical bulletin of national economic and social development of the People’s Republic of China in 2021. (2021). Available online at http://www.stats.gov.cn/xxgk/sjfb/zxfb2020/202202/t20220228_1827971.html. accessed Dec 26, 2022).
   Google Scholar
• Kazibwe J, Gheorghe A, Wilson D, et al. The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review. Value Health. 2022;25(3):385–389.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023;29(2):473–482. DOI:10.1038/s41591-022-02179-2
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139. DOI:10.1186/1471-2288-11-139
   PubMed Web of Science ®Google Scholar
• Djalalov S, Beca J, Ewara EM, et al. A comparison of different analysis methods for reconstructed survival data to inform cost‑effectiveness analysis. Pharmacoeconomics. 2019;37(12):1525–1536. DOI:10.1007/s40273-019-00830-4
   PubMed Web of Science ®Google Scholar
• Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832–842. DOI:10.1016/S1470-2045(20)30110-8
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wu P, He X, et al. Cost-effectiveness analysis of camrelizumab vs. placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China. Front Oncol. 2021;11:790373.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Lin J, Zhu H, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy vs. chemotherapy alone as first-line treatment in patients with esophageal squamous cell carcinoma and PD-L1 CPS of 10 or More. Front Public Health. 2022;10:893387.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu K, Ding D, et al. Pembrolizumab plus chemotherapy as first-line treatment for advanced esophageal cancer: a cost-effectiveness analysis. Adv Ther. 2022;39(6):2614–2629.
   PubMed Web of Science ®Google Scholar
• Liu S, Dou L, Wang K, et al. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. Front Oncol. 2022;12:899966.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Liu C, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111. DOI:10.1186/s13045-022-01325-0
   PubMed Web of Science ®Google Scholar
• Chang AY, Cowling K, Micah AE. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. Lancet. 2019;393(10187):2233–2260.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wushouer H, Han S, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health. 2021;6(7):e006196. DOI:10.1136/bmjgh-2021-006196
   PubMed Web of Science ®Google Scholar
• Tang M, Song P, He J. Progress on drug pricing negotiations in China. Biosci Trends. 2020;13(6):464–468.
   PubMed Web of Science ®Google Scholar
• Fang R, Wang S, Liu Y, et al. Cost-effectiveness analysis of toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma. Adv Ther. 2023;40(3):1019–1030. DOI:10.1007/s12325-022-02402-z
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu K, Ding D, et al. Chemo-immunotherapy regimes for recurrent or metastatic nasopharyngeal carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol. 2022;13:858207.
   PubMed Web of Science ®Google Scholar
• Tian K, Han J, Wang Z, et al. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis. Oral Oncol. 2022;128:105842.
   PubMed Web of Science ®Google Scholar
• Wu M, Qin S, Wang L, et al. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal Cancer. Front Pharmacol. 2022;13:881787.
   PubMed Web of Science ®Google Scholar
• Cao X, Cai H, Li N, et al. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis. Ther Adv Med Oncol. 2022;14:17588359221122733.
   Web of Science ®Google Scholar